Investigational drug · Phase 3
Remigromig
Also called: EYE103, Restoret
Not approved by FDA. In 3 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Diabetic Macular Edema (DME), Neovascular Age-Related Macular Degeneration (NVAMD), Branch Retinal Vein Occlusion (BRVO).
Phase 3Last checked: Nov 19, 2026Latest source record: Nov 10, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
3
3 still active
All registered trials
4
Any phase or sponsor naming "Remigromig"
First trial start
2024
Aug 7, 2024
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "Remigromig", any sponsor or status.
Conditions studied
As listed on its trial records.
- Diabetic Macular Edema (DME)
- Neovascular Age-Related Macular Degeneration (NVAMD)
- Branch Retinal Vein Occlusion (BRVO)
Approved drugs for the same conditions: Wet macular degeneration · Diabetic macular edema · Cardiovascular and metabolic · Ophthalmology
Largest trials
Live from ClinicalTrials.gov: studies naming "Remigromig" as an intervention, largest first.
- A Study of 2 Doses of Remigromig (EYE103) Compared With Ranibizumab (0.5 mg) in Participants With DMEPivotal-lookingActive, not recruiting
EyeBiotech Ltd.Industry
NCT06957080 · 1,054 participants · Start Apr 16, 2025 · Primary completion Jan 11, 2027
Drug: Remigromig; Ranibizumab · For: Diabetic Macular Edema (DME)
Sites: Gilbert, Arizona; Phoenix, Arizona; Scottsdale, Arizona · 164 sites in all
- A Study to Evaluate the Efficacy and Safety of 2 Doses of Remigromig (EYE103) Compared With Ranibizumab (0.5 mg) in Participants With DMEPivotal-lookingActive, not recruiting
EyeBiotech Ltd.Industry
NCT06571045 · 984 participants · Start Aug 7, 2024 · Primary completion Jul 14, 2026
Drug: Ranibizumab; Remigromig · For: Diabetic Macular Edema (DME)
Sites: Scottsdale, Arizona; Fayetteville, Arkansas; Springdale, Arkansas · 183 sites in all
- A Dose-masked Study of Intravitreal Remigromig (EYE103) in Participants With NVAMD or Macular Edema Following BRVOPivotal-lookingRecruiting
EyeBiotech Ltd.Industry
NCT07205887 · 160 participants (planned) · Start Sep 12, 2025 · Primary completion Jun 30, 2028
Drug: Remigromig; Aflibercept 2.0 mg · For: Neovascular Age-Related Macular Degeneration (NVAMD); Branch Retinal Vein Occlusion (BRVO)
Sites: Scottsdale, Arizona; Glendale, California; Modesto, California · 55 sites in all
EyeBiotech Ltd.Industry
NCT05919693 · 33 participants · Start Jun 12, 2023 · Primary completion Aug 26, 2024
Drug: Remigromig · For: Neovascular Age-related Macular Degeneration (NVAMD); Diabetic Macular Edema (DME)
Sites: Phoenix, Arizona; Bakersfield, California; Modesto, California · 32 sites in all
Newest research
PubMed records naming it or its code names, newest first.
- Wnt Pathway Agonism as a Therapeutic Strategy for Retinal Vascular Diseases: A Narrative Review of Evidence to Date.
Angers S, Wykoff CC, Antonetti DA, et al. · Ophthalmol Ther 2026
- Exploring new horizons in neovascular age-related macular degeneration: novel mechanisms of action and future therapeutic avenues.
Shirian JD, Shukla P, Singh RP · Eye (Lond) 2025
- Relationship between phosphatidylinositol synthesis and recovery of 5-hydroxytryptamine-responsive Ca2+ flux in blowfly salivary glands.
Fain JN, Berridge MJ · Biochem J 1979
Also in development for Diabetic Macular Edema (DME)
- 4D-1503E10 vg, eyePhase 35 trials
4D Molecular Therapeutics · Neovascular Age-Related Macular Degeneration (nAMD), Diabetic Macular Edema (DME), Neovascular (Wet) Age-Related Macular Degeneration
- TiespectusEYE201, MK-8748Phase 35 trials
EyeBiotech Ltd. · Macular Degeneration, Age-Related Macular Degeneration, Choroidal Neovascularization
- EYP-1901Phase 34 trials
EyePoint Pharmaceuticals, Inc. · Diabetic Macular Edema, DME, Diabetic Macular Edema (DME)
- OLN324Phase 34 trials
Ollin Biosciences, Inc. · Diabetic Macular Edema (DME), Wet Age Related Macular Degeneration, Wet Age-related Macular Degeneration
- BAT5906Phase 32 trials
Bio-Thera Solutions · Diabetic Macular Edema (DME), Neovascular (Wet) Age-related Macular Degeneration
- Tabirafusp tedromerKSI-501Phase 32 trials
Kodiak Sciences Inc · Diabetic Macular Edema (DME), Wet Age-related Macular Degeneration
- RC28-EPhase 31 trial
RemeGen Co., Ltd. · Diabetic Macular Edema (DME), wAMD
- BGE-102Phase 22 trials
BioAge Labs, Inc. · Diabetic Macular Edema (DME), Obesity and Cardiovascular Risk
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.